May 11, 2017
Salt Lake City, UT, May 11, 2017 — ProLung, Inc., the leader in innovative predictive analytics technology and non-invasive tests for the risk stratification of lung cancer, announced today the successful closing of its private placement. The private offering was expected to raise $5.2
May 04, 2017
Salt Lake City, UT, May 4, 2017 — ProLung, Inc. , a leader in innovative predictive analytics technology and non-invasive biomarkers for the risk stratification of lung cancer, announced today it has been selected to present at the upcoming Cavendish Global Health Impact Forum
February 16, 2017
Salt Lake City, Utah, February 16, 2017 – ProLung, a predictive analytics and risk stratification company that has developed a novel, cost effective, and non-invasive test to identify cancerous and noncancerous lung nodules, announced today that Robin L.
December 10, 2016
Steven C. Eror , President and CEO of ProLung, meets with Gregory C. Simon , White House Cancer Moonshot Task Force, Executive Director in the Office of the Vice President.
November 02, 2016
ProLungDX seeks funds for cancer test; sees eventual IPO – CEO Proprietary Intelligence ProLungDX , a maker of lung cancer detection devices, is looking to raise USD 5.25m from high net worth investors for US commercial development in advance of an expected initial public offering or trade sale,
October 13, 2016
Salt Lake City, UT, USA, October 13, 2016 – ProLungdx™ today announced plans to present its leading-edge innovation for patients at risk of lung cancer during the 2016 BIO Investor Forum in San Francisco, California October 18 and 19, 2016. For the first time in an international biotech
September 07, 2016
Salt Lake City, UT, USA, September 7, 2016 – ProLungdx™ today announced plans to present its ground-breaking innovation for lung cancer patients at the AZBIO’s 2016 White Hat Life Science Investors Conference in Phoenix, Arizona September 21 and 22, 2016.
June 04, 2016
Lung cancer survival rate increases by 73% if caught early. A major lung cancer screening trial, conducted by experts at the University of Liverpool, has found that patients with a high risk of developing lung cancer can be identified with early stage disease and have up to a 73% chance
May 26, 2016
Salt Lake City, Utah, May 25, 2016 – The Board of Directors of Fresh Medical Laboratories Inc., doing business as ProLungdx, today announced the appointment of Dr. John C. Ruckdeschel, M.D. to serve as a Director on the Company’s Board of Directors. Dr.